The ESMO Colloquia are innovative sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community.
The Colloquia are organised by ESMO and supported by the industry in a unique collaboration making them the perfect complement to the scientific and education programme of the Congress.
ESMO Colloquium: Controversies in endometrial cancer: Update on ESMO clinical practice guidelines (CPG) and future treatment direction
Tuesday, 15 September 2020, 13:00-14:30
This educational activity is provided by ESMO and funded by Eisai Europe Ltd.
Resources
- Introduction and clinical implementation of ESMO consensus conference recommendations
- Controversy 1: Which are the biomarkers useful for molecular treatments?
- Controversy 2: which are the indications for chemo-radiotherapy?
- ESMO CPG in endometrial cancer: which are the expected changes?
- Live Q&A
- Controversy 3: which is the management of non-endometrioid histotypes?
- Conclusions
Learning Objectives
- Access new data on Endometrial Cancer
- Learn about how treatment selection can rely on Molecular Biology features
- Reposition the combined modality approach for RT/CT
- Navigate within the various types of Endometrial cancers
- Review the state of the Art and the updates in ESMO Guidelines and Consensus conference
ESMO Colloquium: Precision Medicine Implementation in the Clinic: RET as a potential target in cancer treatment
Tuesday, 22 September 2020, 13:00-14:30
This educational activity is provided by ESMO and supported by Lilly.
Resources
- Introduction
- Introduction to RET mutations and fusions and their incidence for potential use as target in cancer treatment
- RET fusion TKI: Present results and recent developments in Lung cancer
- RET alterations in Thyroid carcinomas: Results and recent update
- RET determination: Present recommendation of the ESMO Precision Medicine working group
- Conclusion: Is RET targeting ready for an agnostic use?
- Live Q&A
Learning Objectives
- Understand the role of RET and its molecular alteration in cancer biology
- Review the present results of RET targeting in Thyroid and Non-Small-Cell Lung carcinomas
- Access the latest ESMO recommendations on RET in Breast cancer
- Consider RET as a possible target for an agnostic treatment approach
ESMO Colloquium: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Wednesday, 23 September 2020, 13:00-14:30
This educational activity is provided by ESMO and supported by Lilly.
Resources
- Is Osimertinib the best single agent if 1st line?
- Should chemotherapy be combined upfront with EGFR TKI?
- Is a combination of anti-angiogenic with EFGR TKI a new standard
- Do immune check point work in EGFR TKI?
- In a multiline setting, what is the best sequencing?
- Conclusions
- Live Q&A
Learning Objectives
- Review the recent outcomes of EGFR mutant metastatic NSCLC treated with 3rd generation EGFR TKI
- Decide whether or not single agent EGFR TKI is still standard of care
- Access recent combination data of EGFR TKI with either chemotherapy or anti-angiogenic or even Immune-checkpoint inhibitors